AR096153A1 - Derivados de pirrolo[2,3-d]pirimidina - Google Patents
Derivados de pirrolo[2,3-d]pirimidinaInfo
- Publication number
- AR096153A1 AR096153A1 ARP140101784A ARP140101784A AR096153A1 AR 096153 A1 AR096153 A1 AR 096153A1 AR P140101784 A ARP140101784 A AR P140101784A AR P140101784 A ARP140101784 A AR P140101784A AR 096153 A1 AR096153 A1 AR 096153A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyrimidine
- pyrrolidinyl
- substituted
- pirrolo
- derivatives
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 3
- -1 2-oxa-6-azaspiro- [3.3] heptyl Chemical group 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005059 halophenyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000005475 oxolanyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) en la que: A es CH₂ o está ausente; R¹ y R² junto con el átomo de nitrógeno, al que están unidos, forman un pirrolidinilo sustituido o un 2-oxa-6-azaespiro-[3.3]heptilo, dicho pirrolidinilo sustituido es un pirrolidinilo sustituido por uno o dos sustituyentes elegidos con independencia entre halógeno, hidroxilo y alquilcarboniloxi; y R³ es halofenilo, alquilsulfonilfenilo, haloalquilfenilo, halopiridinilo, alquiloxadiazolilo, alquiltriazolilo, alquiltetrazolilo, oxolanilo, cicloalquiltetrazolilo o haloalquil-1H-pirazolilo; o una sal o éster farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13166296 | 2013-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096153A1 true AR096153A1 (es) | 2015-12-09 |
Family
ID=48190401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101784A AR096153A1 (es) | 2013-05-02 | 2014-04-30 | Derivados de pirrolo[2,3-d]pirimidina |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9580435B2 (es) |
| EP (1) | EP2991988B1 (es) |
| JP (1) | JP6454689B2 (es) |
| KR (1) | KR20160002857A (es) |
| CN (1) | CN105164133B (es) |
| AR (1) | AR096153A1 (es) |
| AU (1) | AU2014261546B2 (es) |
| BR (1) | BR112015027394A8 (es) |
| CA (1) | CA2907691A1 (es) |
| CL (1) | CL2015003196A1 (es) |
| CR (1) | CR20150555A (es) |
| CY (1) | CY1119114T1 (es) |
| DK (1) | DK2991988T3 (es) |
| EA (1) | EA028123B1 (es) |
| ES (1) | ES2635632T3 (es) |
| HR (1) | HRP20171099T1 (es) |
| HU (1) | HUE035333T2 (es) |
| IL (1) | IL242162B (es) |
| LT (1) | LT2991988T (es) |
| MA (1) | MA38555B1 (es) |
| MX (1) | MX373855B (es) |
| MY (1) | MY182237A (es) |
| NZ (1) | NZ712030A (es) |
| PE (1) | PE20160039A1 (es) |
| PH (1) | PH12015502409A1 (es) |
| PL (1) | PL2991988T3 (es) |
| PT (1) | PT2991988T (es) |
| RS (1) | RS56313B1 (es) |
| SG (1) | SG11201509029PA (es) |
| SI (1) | SI2991988T1 (es) |
| TW (1) | TWI680129B (es) |
| UA (1) | UA116801C2 (es) |
| WO (1) | WO2014177527A1 (es) |
| ZA (1) | ZA201507008B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY191628A (en) | 2013-09-06 | 2022-07-04 | Hoffmann La Roche | Novel triazolo[4,5-d]pyrimidine derivatives |
| BR112017009629A2 (pt) * | 2014-11-07 | 2017-12-19 | Hoffmann La Roche | triazolo [4,5-d] pirimidinas como agonistas do receptor canabinoide 2 |
| EP3475283B1 (en) | 2016-06-23 | 2021-08-11 | F. Hoffmann-La Roche AG | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
| WO2017220516A1 (en) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
| SG11201809678VA (en) * | 2016-06-23 | 2018-11-29 | Hoffmann La Roche | [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor |
| WO2018015088A1 (en) | 2016-06-23 | 2018-01-25 | F. Hoffmann-La Roche Ag | Novel [1,2,31triazolo[4,5-d]pyrimidine derivatives |
| KR20230093251A (ko) | 2020-09-10 | 2023-06-27 | 프리시릭스 엔.브이. | Fap에 대한 항체 단편 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| KR20250034289A (ko) | 2022-05-02 | 2025-03-11 | 프리시릭스 엔.브이. | 사전 표적화 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004502642A (ja) | 2000-02-11 | 2004-01-29 | ブリストル−マイヤーズ スクイブ カンパニー | カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用 |
| AU2003225964B2 (en) | 2002-03-28 | 2008-11-20 | Merck Sharp & Dohme Corp. | Substituted 2,3-diphenyl pyridines |
| DE10219435A1 (de) | 2002-05-02 | 2003-11-13 | Bayer Cropscience Ag | Substituierte Pyrazolo-pyrimidin-4-one |
| AR042667A1 (es) * | 2002-12-26 | 2005-06-29 | Taisho Pharmaceutical Co Ltd | Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico |
| AR051596A1 (es) | 2004-10-26 | 2007-01-24 | Irm Llc | Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios |
| RU2424242C2 (ru) * | 2006-03-30 | 2011-07-20 | Айрм Ллк | Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1 |
| JP2010526836A (ja) * | 2007-05-10 | 2010-08-05 | ジーイー・ヘルスケア・リミテッド | カンナビノイドＣＢ２レセプターに対して活性を有するイミダゾール（１，２−ａ）ピリジン及び関連化合物 |
| WO2009032754A2 (en) * | 2007-08-31 | 2009-03-12 | Kalypsys, Inc. | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease |
| US20100227845A1 (en) | 2007-10-18 | 2010-09-09 | Zhicai Wu | Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| UA104010C2 (en) * | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| CN102574860A (zh) * | 2009-10-15 | 2012-07-11 | 辉瑞大药厂 | 吡咯并[2,3-d]嘧啶化合物 |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| UA111640C2 (uk) | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2 |
| RU2015101818A (ru) | 2012-07-04 | 2016-08-27 | Ф.Хоффманн-Ля Рош Аг | Новые производные адамантила в качестве агонистов каннабиноидных рецепторов 2 |
| UA114657C2 (uk) | 2012-12-07 | 2017-07-10 | Ф. Хоффманн-Ля Рош Аг | Піридин-2-аміди, придатні як агоністи канабіноїдного рецептора 2 |
| US9303012B2 (en) | 2012-12-07 | 2016-04-05 | Hoffman-La Roche Inc. | Pyridine-2-amides useful as CB2 agonists |
| HRP20180672T1 (hr) | 2012-12-07 | 2018-06-01 | F. Hoffmann - La Roche Ag | Novi derivati piridina |
| BR112015009603A2 (pt) | 2012-12-07 | 2017-07-04 | Hoffmann La Roche | novos derivados de pirazina |
| CN105143220B (zh) | 2013-03-07 | 2018-06-22 | 豪夫迈·罗氏有限公司 | 吡唑衍生物 |
| HRP20181141T1 (hr) | 2013-05-02 | 2018-09-21 | F. Hoffmann - La Roche Ag | Derivati purina kao agonisti cb2 receptora |
-
2014
- 2014-04-29 PL PL14720136T patent/PL2991988T3/pl unknown
- 2014-04-29 MX MX2015014081A patent/MX373855B/es active IP Right Grant
- 2014-04-29 WO PCT/EP2014/058648 patent/WO2014177527A1/en not_active Ceased
- 2014-04-29 RS RS20170752A patent/RS56313B1/sr unknown
- 2014-04-29 SI SI201430317T patent/SI2991988T1/sl unknown
- 2014-04-29 AU AU2014261546A patent/AU2014261546B2/en not_active Ceased
- 2014-04-29 PE PE2015002323A patent/PE20160039A1/es active IP Right Grant
- 2014-04-29 UA UAA201510730A patent/UA116801C2/uk unknown
- 2014-04-29 EA EA201591939A patent/EA028123B1/ru not_active IP Right Cessation
- 2014-04-29 HU HUE14720136A patent/HUE035333T2/en unknown
- 2014-04-29 CN CN201480024215.5A patent/CN105164133B/zh active Active
- 2014-04-29 DK DK14720136.2T patent/DK2991988T3/en active
- 2014-04-29 MA MA38555A patent/MA38555B1/fr unknown
- 2014-04-29 JP JP2016511035A patent/JP6454689B2/ja active Active
- 2014-04-29 HR HRP20171099TT patent/HRP20171099T1/hr unknown
- 2014-04-29 NZ NZ712030A patent/NZ712030A/en unknown
- 2014-04-29 BR BR112015027394A patent/BR112015027394A8/pt not_active IP Right Cessation
- 2014-04-29 KR KR1020157031006A patent/KR20160002857A/ko not_active Ceased
- 2014-04-29 EP EP14720136.2A patent/EP2991988B1/en active Active
- 2014-04-29 MY MYPI2015703900A patent/MY182237A/en unknown
- 2014-04-29 PT PT147201362T patent/PT2991988T/pt unknown
- 2014-04-29 ES ES14720136.2T patent/ES2635632T3/es active Active
- 2014-04-29 SG SG11201509029PA patent/SG11201509029PA/en unknown
- 2014-04-29 LT LTEP14720136.2T patent/LT2991988T/lt unknown
- 2014-04-29 CA CA2907691A patent/CA2907691A1/en not_active Abandoned
- 2014-04-30 AR ARP140101784A patent/AR096153A1/es unknown
- 2014-04-30 TW TW103115663A patent/TWI680129B/zh not_active IP Right Cessation
-
2015
- 2015-09-21 ZA ZA2015/07008A patent/ZA201507008B/en unknown
- 2015-10-14 CR CR20150555A patent/CR20150555A/es unknown
- 2015-10-16 PH PH12015502409A patent/PH12015502409A1/en unknown
- 2015-10-19 IL IL242162A patent/IL242162B/en active IP Right Grant
- 2015-10-26 US US14/923,186 patent/US9580435B2/en active Active
- 2015-10-30 CL CL2015003196A patent/CL2015003196A1/es unknown
-
2017
- 2017-07-24 CY CY20171100785T patent/CY1119114T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096153A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
| CL2015002520A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso. | |
| CY1120635T1 (el) | Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης | |
| MX373713B (es) | Compuestos pirazolopirimidina. | |
| AR094978A1 (es) | Derivados de pirazol agonistas de receptores canabinoides | |
| AR094857A1 (es) | Derivados de pirrolo[2,3-d]pirimidina | |
| AR094342A1 (es) | Derivados de ácido borónico útiles como agentes antimicrobianos | |
| AR094668A1 (es) | Amidas como moduladores de canales de sodio | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| UY35333A (es) | Compuestos de azabencimidazol | |
| CR20140294A (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| AR093804A1 (es) | Derivados de pirazina agonistas de receptores cb2 | |
| MX373716B (es) | Compuesto de pirazol-amida y sus usos farmaceuticos. | |
| AR096152A1 (es) | Derivados de purina | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| MY178371A (en) | Pharmaceutical preparation | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
| AR087274A1 (es) | Derivados de amidas heterociclicas como antagonistas de receptores p2x7 | |
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| AR100440A1 (es) | Derivados de carboxamida como inhibidores selectivos de smurf1 | |
| AR102539A1 (es) | Triazolo[4,5-d]pirimidinas | |
| CY1125355T1 (el) | Πεντακυκλικη ενωση | |
| EA201491852A1 (ru) | Новые пиразольные соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |